Apolipoprotein C3 inhib 
Welcome,         Profile    Billing    Logout  
 4 Companies  3 Products   3 Products   0 Diseases   3 Trials   123 News 


12345678910»
  • ||||||||||  LY3875383 / Eli Lilly
    Journal:  APOC3 siRNA and ASO therapy for dyslipidemia. (Pubmed Central) -  Feb 28, 2024   
    Inhibition of apoC3 is effective across all the spectrum of hypertriglyceridemia, might have a favorable effect on hepatic steatosis (NAFLD) and the effect of apoC3 inhibition on cardiovascular risk is not limited to its effect on plasma triglycerides. APOC3 GalNAc-conjugated ASO and siRNA are both effective in decreasing plasma apoC3 and triglyceride levels.
  • ||||||||||  Journal:  The Role of Triglycerides in Atherosclerosis: Recent Pathophysiologic Insights and Therapeutic Implications. (Pubmed Central) -  Jan 30, 2024   
    In conclusion, this review underscores the importance of a nuanced approach to understanding the role of triglycerides in atherosclerosis and their potential as a therapeutic target. Further research is needed to unravel the complex interplay between triglycerides, triglyceride-rich lipoproteins, and associated factors in atherosclerosis pathogenesis and refine triglyceride-targeted therapeutic strategies.
  • ||||||||||  Review, Journal:  Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia. (Pubmed Central) -  Jan 8, 2024   
    Inhibition of ANGPTL3 or the ANGPTL3/8 complex upregulates LPL and facilitates the hydrolysis and clearance of triglyceride-rich lipoproteins (TRL) (LPL-dependent mechanisms), whereas ApoC-III inhibitors contribute to the management and clearance of TRL through both LPL-dependent and LPL-independent mechanisms making it possible to successfully lower TG in subjects completely lacking LPL (familial chylomicronemia syndrome). Most of these agents are biologicals including monoclonal antibodies (mAb), antisense nucleotides (ASO), small interfering RNA (siRNA), or CRISPR-cas gene editing strategies.
  • ||||||||||  Review, Journal:  Apolipoprotein C3: Form begets function. (Pubmed Central) -  Nov 17, 2023   
    There is still much to learn about the mechanisms of action of different forms and pools of APOC3 in atherosclerosis and CVD, and whether APOC3 inhibition would prevent CVD risk in patients on LDL-cholesterol lowering medications. KEYWORDS: Apolipoproteins, Atherosclerosis, Inflammation, LDL, Triglycerides, VLDL.
  • ||||||||||  Review, Journal:  Severe hypertriglyceridemia: Existing and emerging therapies. (Pubmed Central) -  Nov 7, 2023   
    Genetic discoveries have allowed for the development of novel pathway-specific therapeutics targeting LPL modulating proteins. New targets directed towards inhibition of apolipoprotein C-III (apoC-III), angiopoietin-like protein 3 (ANGPTL3), angiopoietin-like protein 4 (ANGPTL4), and fibroblast growth factor-21 (FGF21) offer far more efficacy in treating the various phenotypes of sHTG and opportunities to reduce the risk of acute pancreatitis and atherosclerotic cardiovascular disease events.
  • ||||||||||  Praluent (alirocumab) / Sanofi, Regeneron, Juxtapid (lomitapide) / Novelion, Chiesi, Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Daiichi Sankyo
    Review, Journal:  Advances in Treatment of Dyslipidemia. (Pubmed Central) -  Sep 13, 2023   
    Our review demonstrates the pivotal roles played by each of these drugs in targeting specific parameters of lipid metabolism. We outline the future landscape of dyslipidemia treatment, envisaging a more tailored and effective therapeutic approach to address this widespread medical concern.
  • ||||||||||  Review, Journal:  Sugar and Dyslipidemia: A Double-Hit, Perfect Storm. (Pubmed Central) -  Sep 9, 2023   
    The end outcome is a dual, synergistic, and harmful action that encourages atherogenesis. Thus, considering the growing concerns regarding the connection between sugar consumption and cardiometabolic disease, current research strongly supports the actions of public health organizations aimed at reducing sugar intake, including dietary guidance addressing "safe" limits for sugar consumption.
  • ||||||||||  Journal:  Unanticipated Enhancement of Intestinal TG Output by Apoc3 ASO Inhibition. (Pubmed Central) -  Sep 8, 2023   
    These data demonstrate that the reduction of intestinal triglyceride output does not contribute to the potent plasma triglyceride-lowering observed with this novel therapy for hypertriglyceridemia. Further studies are required to explore the mechanism of this intestinal effect.
  • ||||||||||  fenofibrate / Generic mfg.
    Journal:  Medical management of hypertriglyceridemia in pancreatitis. (Pubmed Central) -  Jul 8, 2023   
    Further studies are required to explore the mechanism of this intestinal effect. Patients with HTG-AP require acute and long-term management of HTG with the goal of reducing and maintaining triglyceride levels to less than 500?mg/dl.
  • ||||||||||  Waylivra (volanesorsen) / Novartis, SOBI
    Journal:  APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia. (Pubmed Central) -  Jun 19, 2023   
    In all 3 trials individually, a strong inverse correlation was present between the baseline HFF and the change in HFF in the volanesorsen groups, but not in the placebo groups. In conclusion, apoC-III inhibition with volanesorsen has favorable effects in HFF in patients with different etiologies of hypertriglyceridemia.
  • ||||||||||  Journal:  Recent Apolipoprotein CIII trials. (Pubmed Central) -  Nov 10, 2022   
    Then, we will examine the lipid-lowering potential of the pharmacological inhibition of ApoCIII based on the results of clinical trial employing Volansesorsen, the first approved antisense therapeutic oligonucleotide against ApoCIII mRNA. The future perspectives for ApoCIII inhibition will be also revised.
  • ||||||||||  ezetimibe / Generic mfg.
    Review, Journal:  Remnant cholesterol and atherosclerotic cardiovascular disease: Metabolism, mechanism, evidence, and treatment. (Pubmed Central) -  Nov 4, 2022   
    The lipids-lowering treatments such as statins and ezetimibe targeted on low-density lipoprotein cholesterol (LDL-C) have always been the first-line therapy for ASCVD...However, the standardized detection of RC was still controversial, and more studies on appropriate treatments of elevated RC are urgently needed. These positive trials may benefit more patients at high ASCVD risks worldwide in the future.
  • ||||||||||  Deep Phenotyping APOC3 Knockouts in a Population With High Consanguinity (Virtual Only) -  Oct 13, 2022 - Abstract #AHA2022AHA_8261;    
    In conclusion, by leveraging a highly consanguineous cohort, we have identified and phenotyped APOC3 KOs that have, hitherto, not been identified elsewhere. We did not observe APOC3 LOF to confer protection in complete KOs and observed other biomarker and phenotypic associations; these findings should inform existing therapeutic programs targeting APOC3.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Clinical, Review, Journal:  Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention. (Pubmed Central) -  Sep 20, 2022   
    High-dose EPA in the form of icosapent ethyl has been demonstrated to have cardiovascular benefit on top of statins in persons with elevated triglycerides at high ASCVD risk. Ongoing clinical trials are evaluating novel selective therapies such as apoC3 and ANGPTL3 inhibitors.
  • ||||||||||  Waylivra (volanesorsen) / Novartis
    Retrospective data, Journal:  Efficacy and safety of the apolipoprotein C-III inhibitor Volanesorsen: a systematic evaluation and meta-analysis. (Pubmed Central) -  May 7, 2022   
    In addition, HDL-C increased (MD = 46.01% 95% CI = 41.03 to 50.99, P = 0.41, I = 0%), NHDL-C decreased (MD = -32.12%; 95% CI = -44.39 to -19.85, P = 0.11, I = 55%), VLDL-C decreased (MD = -65.88%; 95% CI = -83.97 to -47.79, P = 0.71, I = 0%), apo A1 increased (MD = 13.12%; 95% CI = 7.83 to 18.40, P = 0.72, I = 0%), and apoB increased (MD = 7.94 %; 95% CI = -1.90 to 17.78, P = 0.54, I = 0%) all suggest that volanesorsen has an overall FCS with a therapeutic effect. However, LDL-C increased (MD = 99.59%; 95% CI = 69.19 to 130.00, P = 0.61, I = 0%) and apo B48 decreased (MD = 82.89%; 95% CI = -100.88 to -64.91, P = 0.42, I = 0%), showing an inverse effect, suggesting that volanesorsen's did not target all proteins of lipid metabolism.
  • ||||||||||  Review, Journal:  Childhood Hypertriglyceridemia: Is It Time for a New Approach? (Pubmed Central) -  Apr 26, 2022   
    Management of HTG is dependent on its etiology, concomitant symptoms, and degree of TG elevation. The last two decades have seen remarkable changes in drug development, specifically those that act through the lipoprotein lipase complex, including new targeted treatments such as inhibitors of apolipoprotein C3 and angiopoietin-like protein 3.
  • ||||||||||  olezarsen (AKCEA-APOCIII-LRx) / Novartis, Ionis
    Clinical, Journal:  Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. (Pubmed Central) -  Apr 9, 2022   
    P2
    The last two decades have seen remarkable changes in drug development, specifically those that act through the lipoprotein lipase complex, including new targeted treatments such as inhibitors of apolipoprotein C3 and angiopoietin-like protein 3. Olezarsen significantly reduced apoC-III, triglycerides, and atherogenic lipoproteins in patients with moderate hypertriglyceridaemia and at high risk for or with established cardiovascular disease.
  • ||||||||||  ezetimibe / Generic mfg.
    Review, Journal:  A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy? (Pubmed Central) -  Apr 9, 2022   
    Large clinical outcome trials in relevant populations are still required to confirm the long-term efficacy, safety and cost effectiveness of these potent agents for mitigating the complications of HTG. Beyond targeting severe chylomicronaemia in the prevention of acute pancreatitis, both agents could be useful in addressing residual risk of ASCVD due to TRLs in patients receiving best standard of care, including behavioural modifications, statins, ezetimibe, fibrates and proprotein convertase subtilisin/kexin type 9 inhibitors.
  • ||||||||||  Waylivra (volanesorsen) / Novartis
    Review, Journal:  Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia. (Pubmed Central) -  Feb 25, 2022   
    In this review, the latest and experimental therapies for the management of hypertriglyceridemia are presented. Specifically, ongoing trials evaluating novel apolipoprotein C-III inhibitors, ω-3 fatty acids, as well as fibroblast growth 21 analogues are discussed.
  • ||||||||||  Waylivra (volanesorsen) / Novartis
    Journal:  Targeting ApoC3 Paradoxically Aggravates Atherosclerosis in Hamsters With Severe Refractory Hypercholesterolemia. (Pubmed Central) -  Feb 22, 2022   
    Although targeting ApoC3 by antisense oligonucleotide (ASO), Volanesorsen markedly reduces plasma TG level and increase high-density lipoprotein cholesterol (HDL-C) in patients with hypertriglyceridemia (HTG), the cholesterol-lowering effect of ApoC3 inhibition and then the consequential outcome of atherosclerotic cardiovascular disease (ASCVD) have not been reported in patients of familial hypercholesterolemia (FH) with severe refractory hypercholesterolemia yet...Further analysis of blood biological parameters revealed that lacking ApoC3 resulted in abnormal platelet (PLT) indices, which could potentially contribute to atherosclerosis in LDLR hamsters. In this study, our novel findings provide new insight into the application of ApoC3 inhibition for severe refractory hypercholesterolemia and ASCVD.
  • ||||||||||  Review, Journal:  New Therapies for Lowering Triglyceride-Rich Lipoproteins: JACC Focus Seminar 3/4. (Pubmed Central) -  Dec 29, 2021   
    New therapies targeting select catalytic pathways in TRL metabolism reduce atherosclerosis in experimental models, and concentrations of TRLs in patients with a vast range of triglyceride levels. Clinical trials with inhibitors of angiopoietin-like 3 protein and apolipoprotein C-III will be required to provide further guidance on the potential contribution of these emerging therapies in the paradigm of cardiovascular risk management in patients with elevated remnant cholesterol.